BridgeBio Pharma/$BBIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BridgeBio Pharma
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
- Ticker
- $BBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,001
- Headquarters
- Palo Alto, United States
- Website
- bridgebio.com
BridgeBio Pharma Metrics
BasicAdvanced
$15B
-
-$3.04
-
-
Price and volume
Market cap
$15B
52-week high
$93.42
52-week low
$60.22
Average daily volume
3M
Financial strength
Current ratio
2.092
Quick ratio
1.959
Long term debt to equity
-1.71
Total debt to equity
-2.043
Interest coverage (TTM)
-1.66%
Profitability
EBITDA (TTM)
-348.362
Gross margin (TTM)
94.34%
Net profit margin (TTM)
-59.84%
Operating margin (TTM)
-37.34%
Effective tax rate (TTM)
-0.19%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
-13.97%
Return on equity (TTM)
32.30%
Valuation
Price to revenue (TTM)
15.461
Price to book
-5.64
Price to tangible book (TTM)
-5.58
Price to free cash flow (TTM)
-39.245
Free cash flow yield (TTM)
-2.55%
Free cash flow per share (TTM)
-1.91
Growth
Revenue change (TTM)
167.27%
Earnings per share change (TTM)
-27.48%
3-year revenue growth (CAGR)
364.61%
3-year earnings per share growth (CAGR)
-8.12%
What the Analysts think about BridgeBio Pharma
Analyst ratings (Buy, Hold, Sell) for BridgeBio Pharma stock.
Analyst projections of the future price of BridgeBio Pharma stock.
Bulls say / Bears say
Attruby generated $253.2 million of US net product revenue in the third quarter, up 134% year on year and about $31 million sequentially. Growth was led by treatment-naïve patients and increased first-line share. (BridgeBio Pharma)
Independent real-world studies found lower clinical-worsening and hospitalisation risks with acoramidis than with tafamidis, including an 18% lower composite risk in a matched analysis of 2,684 patients. If these findings translate into treatment choices, they could strengthen Attruby’s case with doctors and payers. (BridgeBio Pharma)
BridgeBio has three potential launches beyond Attruby: BBP-418 has an FDA target date of 27 November 2026, while infigratinib and encaleret have target dates in February and May 2027. Approval could add new rare-disease products to its commercial base. (BridgeBio Pharma)
The reported third-quarter operating loss of $11.6 million was helped by a one-off $75 million Bayer milestone. Management still expected average operating losses of $90 million to $100 million per quarter for 2026, so the business has yet to reach sustained profitability. (BridgeBio Pharma, The Motley Fool)
Attruby’s future growth depends on winning over doctors who have not yet prescribed it: management said more than 60% of prescribers had yet to try the drug, while some rivals are better resourced. Slower uptake among this broader group could constrain sales growth. (The Motley Fool)
At 30 September, BridgeBio reported $1.5 billion of cash, but also $2.48 billion of notes, $884 million of deferred royalty obligations and $942 million of Series A preferred stock. These substantial financing claims could limit the value accruing to ordinary shareholders. (BridgeBio Pharma)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
BridgeBio Pharma Financial Performance
Revenues and expenses
BridgeBio Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
BridgeBio Pharma News
AllArticlesVideos
Funds containing BridgeBio Pharma
AllUSDEURGBP
Fund name | Fund size | $BBIO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.90% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.90% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.16% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.16% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.